Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (371-380 of 583) with videos related to

Pageof 59
Sort By:
Leukemia|February 16, 2011
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720M R Baer, S L George, B L Sanford, et al.
Leukemia|July 21, 2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2A-K Eisfeld, J Kohlschmidt, K Mrózek, et al.
Cancer Research|February 24, 2001
The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemiaS P Whitman, M P Strout, G Marcucci, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|May 18, 2001
Midodrine prevents orthostatic intolerance associated with simulated spaceflightC D Ramsdell, T J Mullen, G H Sundby, et al.
Nature Reviews. Disease Primers|May 10, 2016
Acute myeloid leukaemiaAsim Khwaja, Magnus Bjorkholm, Rosemary E Gale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Susan P Whitman, et al.
Cancer Research|September 29, 1998
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtypeC D Bloomfield, D Lawrence, J C Byrd, et al.
Blood|December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Blood|December 31, 1997
Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B studyK Mrózek, K Heinonen, D Lawrence, et al.
British Journal of Haematology|August 2, 2016
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemiaBhavana Bhatnagar, Ann-Kathrin Eisfeld, Deedra Nicolet, et al.
Pageof 59

Showing results (371-380 of 583) with videos related to

Sort By:
Pageof 59
Leukemia|February 16, 2011
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720M R Baer, S L George, B L Sanford, et al.
Leukemia|July 21, 2016
Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2A-K Eisfeld, J Kohlschmidt, K Mrózek, et al.
Cancer Research|February 24, 2001
The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemiaS P Whitman, M P Strout, G Marcucci, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|May 18, 2001
Midodrine prevents orthostatic intolerance associated with simulated spaceflightC D Ramsdell, T J Mullen, G H Sundby, et al.
Nature Reviews. Disease Primers|May 10, 2016
Acute myeloid leukaemiaAsim Khwaja, Magnus Bjorkholm, Rosemary E Gale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Susan P Whitman, et al.
Cancer Research|September 29, 1998
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtypeC D Bloomfield, D Lawrence, J C Byrd, et al.
Blood|December 2, 2004
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222Joseph O Moore, Stephen L George, Richard K Dodge, et al.
Blood|December 31, 1997
Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B studyK Mrózek, K Heinonen, D Lawrence, et al.
British Journal of Haematology|August 2, 2016
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemiaBhavana Bhatnagar, Ann-Kathrin Eisfeld, Deedra Nicolet, et al.
Pageof 59